Subscribe for Free

Radar / Deal

💰

Bengaluru-based Biotech Zumutor Biologics Secures $7.3M for Immuno-Oncology Clinical Trials

Zumutor Biologics eyes global Phase 2 trials with $7.3M infusion

HealthTech 🔥 Strong Signal 🟡 Warm $7.3M

⏰ Why Now

The successful validation of early clinical signals in Phase 1 trials has cleared the path for aggressive global expansion and combination studies.

Stage

series b

Amount Raised

$7.3M

🏛️ Investors

🏛️ Accel Lead 🏛️ Bharat Innovation Fund Lead 🏛️ Premji Invest 👼 Ashish Kacholia 🏠 Raj Dandu Family Office

📈 Known Traction at Raise

Ongoing US FDA Phase 1 trials with encouraging early clinical signals.

💡 Investor Thesis

Investors are backing the platform's ability to demonstrate efficacy in hard-to-treat cancer types, combined with the company's dual-geography operational efficiency.

📊 Market Signal

The rise of cross-border Indian-US biotech firms developing proprietary IP for the global oncology market.

🎯 Key Takeaway for Founders

For biotech founders, success hinges on securing early-stage clinical signals that justify the high capital expenditure required for FDA-compliant global trials.

✍️ Editor's Note

A notable example of Indian deep-tech biotech moving from early-stage research to significant clinical milestones in the US market.

Deal Overview

Bengaluru and US-based biotech firm Zumutor Biologics has raised $7.3 million in a Pre-Series B funding round. The investment was led by existing backers Accel and Bharat Innovation Fund, with fresh participation from Premji Invest, Ashish Kacholia, and the Raj Dandu Family Office.

Company Background and Tech

Founded by Kavitha Iyer Rodrigues, Zumutor focuses on immuno-oncology, specifically developing therapies that leverage the body’s innate immune system to combat cancer. Its flagship program, ZM008, is a first-in-class natural killer (NK) cell checkpoint therapy designed to enhance the immune response against malignant cells.

Use of Funds

The company plans to deploy the capital to:

Complete the ongoing US FDA Phase 1 clinical trial for ZM008.
Support Phase 1B expansion cohorts.
Initiate global Phase 2 studies, including trial sites within India.
Fund combination studies across multiple cancer indications.

Market Context

Zumutor represents a maturing wave of Indian biotech startups transitioning from discovery to global clinical development. By targeting hard-to-treat tumors, the firm is positioning itself within the competitive international immuno-oncology landscape.

More Trending in HealthTech

Think Bioscience Raises $55M Series A

Think Bioscience has secured $55M in an oversubscribed Series A to advance a platform that treats drug discovery as a biological survival game rather than just a computational problem. Instead of relying solely on digital simulations to find binding pockets on difficult proteins, Think “programs” microbes to generate millions of small molecules. The system is […]

Biotech ⭐ Featured

Emergent

Mukund Jha (ex-Dunzo) is back, and his second act is moving at a velocity that makes quick-commerce look sluggish. Emergent, a “vibe-coding” platform that uses AI agents to build full-stack apps from natural language, has raised a $70M Series B at a $300M valuation. The round was co-led by Khosla Ventures and SoftBank Vision Fund […]

AI ⭐ Featured